KRAS and cancer: Knocking-down KRAS in DLD-1G13D cells resulted in cells more resistant to oxaliplatin, but not to irinotecan, and 5FU, standard chemotherapeutic agents for CRC, and not to doxorubicin, broad spectrum chemotherapeutic agent for other major cancers.